Hormone Replacement Therapy and Breast Cancer Screening;Hormonsubstitution und Mammakarzinomscreening

Geburtshilfe und Frauenheilkunde

Volumn 63, Issue 10, 2003, Pages 999-1003

  Keck, C ^a   Tempfer, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; PROGESTERONE;

ADULT; AGED; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ESTROGEN DEFICIENCY; FAMILY HISTORY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MENOPAUSE; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0142184437     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-42736     Document Type: Review

References (50)

1. Banks E. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 2001; 8: 29-34
2. Bilimoria MM, Winchester DJ, Sener SF et al. Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics. Ann Surg Oncol 1999; 6: 200-207
3. Boyd NF, Lockwood GA, Martin LJ et al. Mammographic densities and risk of breast cancer among subjects with a family history of the disease. J Natl Cancer Inst 1999; 91: 1404-1408
4. Byng JW, Boyd NF, Fishell E et al. The quantitative analysis of mammographic densities. Phys Med Biol 1994; 39: 1629-1638
5. Carmanns, B, Fiedler V, Poleska W. Interdisziplinäre Kooperation von Radiologen, Pathologen und Gynäkologen bei der Differenzialdiagnose des frühen Mammakarzinoms und benigner nicht tastbarer Herdbefunde. Geburtsh Frauenheilk 2001 61: 857-862
6. Chen CL, Weiss NS, Newcomb P et al. Hormone replacement therapy in relation to breast cancer. J Am Med Assoc 2002; 287: 734-741
7. Chetrite GS, Pasqualini JR. The selective estrogen enzyme modulator (SEEM) in breast cancer. J Steroid Biochem Mol Biol 2001; 76: 95-104
8. Chetrite GS, Kloosterboer HJ, Philippe JC et al. Effect of Org OD14 (LI-VIAL) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MCF-7 and T-47 D, and the hormone-independent MDA-MB-231, breast cancer cell lines. Anticancer Res 1999; 19: 269-275
9. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD et al. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002; 9: 110-116
10. Cohen ML, Lohnson A, Shekdar J. Effect of hormone replacement therapy on cancer detection by mammography [letter]. Lancet 1997; 349: 1624
11. Colacurci N, Fornaro F, De Franciscis P et al. Effects of a short-term suspension of hormone replacement therapy on mammographic density. Fertil Steril 2001; 76: 451-455
12. Colacurci N, Fornaro F, De Franciscis P et al. Effects of different types of hormone replacement therapy on mammographic density. Maturitas 2001; 40: 159-164
13. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-1059
14. Crane CEB, Luke CG, Rogers JM, Playford PE, Roder DM. An analysis of factors associated with interval as opposed to screen-detected breast cancers, including hormone therapy and mammographic density. The Breast 2002; 11: 131-136
15. Egarter C, Eppel W, Vogel S et al. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas 2001; 40: 165-171
16. El-Bastawissi AY, White E, Mandelson MT, Taplin SH. Reproductive and hormonal factors associated with mammographic density by age (United States). Cancer Causes Controll 2000; 11: 955-963
17. Engel J, Baumert J, Dirschedl P, Sauer H, Hölzel D. Wirksamkeit der Selbstuntersuchung, Palpation und Mammographie zur Früherkennung des Mammakarzinoms: erste Ergebnisse der Feldstudie München. Geburtsh Frauenheilk 2000; 60: 155-164
18. Gilliland D, Joste N, Stauber PM et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2000; 92: 743-749
19. Greendale GA, Reboussin BA, Sie A et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999; 130: 262-269
20. Grodstein F, Stampfer MJ, Colditz GA et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-1775
21. Harvey AJ, Pinkerton JY, Herman CR. Short-term cessation of hormone replacement therapy and improvement in mammographic specificity. J Natl Cancer Inst 1997; 89: 1623-1625
22. Kavanagh AM, Giles GG, Mitchell H, Cawson J. The sensitivity, specificity, and positive predictive value of screening mammography and symptomatic status. J Med Screen 2000; 7: 105-110
23. Kavanagh AM, Mitchell H, Giles GG. Hormone replacement therapy and accuracy of mammographic screening. Lancet 2000; 355: 270-274
24. Klimberg VS. Advances in the diagnosis and excision of breast cancer. Am Surg 2003; 69: 11-14
25. Laya MB, Larson EB, Taplin SH, White D. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 1996; 88: 643-649
26. Li C, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000; 88: 2570-2577
27. Liberman L, Menell JH. Breast imaging reporting and data system (BI-RADS). Radiol Clin North Am 2002; 40: 409-430
28. Litherland JC, Evans AJ, Wilson AR. The effect of hormone replacement therapy on recall rate in the National Healths Service Breast Screening Programme. Clin Radiol 1997; 52: 276-279
29. Litherland JC, Stallard S, Hole D, Cordiner C. The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol 1999; 54: 285-288
30. Lundstrom E, Christow A, Kersemaekers W et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002; 186: 717-722
31. Magnusson C, Holmberg L, Nordén T et al. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996; 38: 325-334
32. Mandelson MT, Oestreicher N, Porter PL et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000; 92: 1081-1087
33. McNicholas MMJ, Heneghan JP, Milner MH et al. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. Am J Roentgenol 1994; 163: 311-315
34. Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001; 358 (9290): 1340-1342
35. Porter PL, El-Bastawissi AY, Mandelson MT et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Nat Cancer Inst 1999; 91: 2020-2028
36. Riggs BL. Tibolone as an alternative to estrogen for the prevention of postmenopausal osteoporosis in selected postmenopausal women. J Clin Endocrinol Metab 1996; 81: 2417-2418
37. Rosenberg RD, Hunt WC, Williamson MR et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 1998; 209: 511-518
38. Ross LA, Alder EM. Tibolone and climacteric symptoms. Maturitas 1995; 21: 127-136
39. Ruhland F, Heinrich J, Budner M, Jeschke A. Diagnostische Wertigkeit von Mammographie und Mammasonographie bei klinisch okkulten Mammaläsionen. Geburtsh Frauenheilk 2000; 60: 104-110
40. Rutter CM, Mandelson MT, Laya MB et al. Changes in breast density associated with initiation, descontinuation, and continuing use of hormone replacement therapy. J Am Med Assoc 2001; 285: 171-176
41. Saftlas AF, Wolfe JN, Hoover RN et al. Mammographic parenchymal patterns as indicators of breast cancer risk. Am J Epidemiol 1989; 129: 518-526
42. Sala E, Warren R, McCann J et al. Mammographic parenchymal patterns and mode of detection: implications for the breast screening programme. J Med Screen 1998; 5: 207-212
43. Schairer C, Lubin J, Troisi R et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000; 283: 485-491
44. Séradour B, EstPve J, Heid P, Jacquemier J. Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhône programme. J Med Screen 1999; 6: 99-102
45. Stallard S, Litherland JC, Cordiner CM et al. Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. Br Med J 2000; 320: 348-349
46. Thurfjell EL, Holmberg LH, Persson IR. Screening mammography: sensitivity and specificity in relation to hormone replacement therapy. Radiology 1997; 203: 339-341
47. Wang H, Bjurstam N, Björndal H et al. Interval cancers in the Norwegian breast cancer screening program: frequency, characteristics and use of HST. Int J Cancer 2001; 94: 594-598
48. Willis DB, Calle EE, Miracle-McMahil HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7: 449-457
49. Wolfe JN. Breast patterns as an index of risk for developing breast cancer. Am J Roentgenol 1976; 126: 1130-1137
50. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321-333